Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials. J of Skin 2023, 7 (2), s129. https://doi.org/10.25251/skin.7.supp.129.